Abstract
There is an increasing interest in the potential role of low molecular weight heparins (LMWHs) in the management of cancer patients. These antithrombotic agents have generated particular excitement because they have been proved useful in both the prevention and treatment of venous thromboembolism (VTE) in patients with malignancy. Recent reports are, at the same time, highlighting a potential role of LMWHs on patient survival due to their presumed antineoplastic action. This review will discuss the most recent reports and patents on these topics.
| Lingua originale | English |
|---|---|
| pagine (da-a) | 159-161 |
| Numero di pagine | 3 |
| Rivista | Recent Patents on Anti-Cancer Drug Discovery |
| Volume | 3 |
| Stato di pubblicazione | Published - 2008 |